PEG ilodecakin

Drug Profile

PEG ilodecakin

Alternative Names: AM 0010; PEG-ilodecakin; PEG-rHuIL-10; PEGylated Human IL-10; PEGylated recombinant human Interleukin-10

Latest Information Update: 18 Jul 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Developer ARMO Biosciences
  • Class Anti-inflammatories; Antineoplastics; Immunotherapies; Interleukins; Polyethylene glycols
  • Mechanism of Action Interleukin-10 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase I Breast cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cancer
  • Preclinical Fibrosis; Hypercholesterolaemia; Inflammatory bowel diseases

Most Recent Events

  • 15 Jun 2017 Updated adverse events and efficacy data from a phase I trial in Solid tumours presented at the (ADNM)
  • 03 Jun 2017 Interim adverse events, efficacy and immunogenicity data from a phase I trial in Colorectal cancer (SC) presented at the 53rd annual meeting of the American Society of Clinical Oncology (ASCO-2017) .
  • 02 Jun 2017 Interim efficacy and adverse events data from a phase I trial in Solid tumours presented 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top